Core Insights - Strata Critical Medical, Inc. reported a strong Q4 2025 with organic growth of 35%, exceeding expectations and leading to a full-year performance that surpassed guidance on all fronts [1][24] - The company is raising its revenue and adjusted EBITDA guidance for 2026 due to strong volumes and new customer acquisitions [1][29] Financial Performance - Full-year 2025 revenue reached $197.1 million and adjusted EBITDA was $14.1 million, both exceeding the high end of guidance [24] - Q4 2025 revenue was $66.8 million, driven by logistics growth of 35.3% to $49.2 million compared to $36.4 million in the prior year [24][27] - Clinical revenue in Q4 2025 was $17.6 million, significantly up from $2.8 million in Q3 2025, reflecting the impact of the Keystone acquisition [24][25] Growth Strategy - Continued acquisitions of smaller businesses are a key part of the company's strategy to accelerate growth and expand geographically [5][15] - The company expects to maintain an average annualized adjusted EBITDA growth rate of at least 30% over the coming years, driven by successful execution of its M&A strategy [15][16] Regulatory Environment - Recent regulatory changes are seen as beneficial for Strata Critical Medical, particularly in incentivizing the pursuit of medically complex organs [8][10] - The company is well-positioned with a customer base that is over-indexed to larger, more sophisticated transplant centers, which are favored under new regulations [10][11] Operational Highlights - The company ended the year with a fleet of approximately 30 dedicated or owned aircraft and plans to add two new owned aircraft to support new geographies in 2026 [12][13] - Logistics gross profit increased by 39.5% to $10.6 million in Q4 2025, driven by strong revenue growth and improved gross margins [27] Future Outlook - The company raised its 2026 revenue guidance range to $260–$275 million from $255–$270 million previously, and adjusted EBITDA guidance to $29–$33 million from $28–$32 million [29] - Despite a modest sequential revenue decline expected in Q1 2026, the company anticipates a sequential improvement in revenue and margin in the second quarter and the latter half of the year [31]

Financial Performance & Acquisitions - Strata's Q3 2025 revenue reached $493 million, a 37% year-over-year increase, with 29% organic growth excluding the Keystone acquisition[5] - The acquisition of Keystone Perfusion contributed approximately $28 million to Strata's Q3 2025 revenue[6] - Adjusted EBITDA for Q3 2025 was $42 million, representing an 85% margin[5] - Strata sold its passenger business to Joby Aviation for $125 million[14] - Strata acquired Keystone Perfusion for $124 million upfront, with potential earn-outs of $23 million based on gross profit targets[15] Market Position & Growth Strategy - Strata estimates its market share to be approximately 30% in air logistics and 15% in ground logistics for organ transport[11] - The company is focused on expanding its transplant clinical services, particularly Normothermic Regional Perfusion (NRP), driven by a 20%+ CAGR in Donation after Circulatory Death (DCD) donors[43] - Strata aims to increase aircraft utilization and improve operating costs by expanding into other time-critical logistics verticals[55] Organ Transplant Trends - The distance of heart, liver, and lung transplants has increased by 64% from 2018 to 2024 due to regulatory changes and new technologies[39] - Normothermic Regional Perfusion (NRP) penetration of DCD donors has increased to approximately 40% by Q3 2025[43] - U S heart, liver, and lung transplants have grown at a CAGR of 38% from 2010-2024[27]

Company Overview - Strata Critical Medical, Inc. provides time-critical logistics solutions and specialized medical services to healthcare providers across the United States, focusing on strategic expansion through acquisitions and organic growth [2] - The company's subsidiary, Trinity Medical Solutions, is a leader in the air and ground transportation of human organs for transplant, utilizing an asset-light platform for efficient logistics delivery [2] Upcoming Events - Will Heyburn, Co-Chief Executive Officer and Chief Financial Officer of Strata, will present at the 2025 Jefferies Industrials Conference on September 4, 2025, at 11:30 am ET, with a webcast available for investors [1] Strategic Focus - The company is actively expanding its portfolio of services, indicating a commitment to growth and adaptation within the healthcare logistics sector [2]

Core Viewpoint - Strata Critical Medical, Inc. has successfully divested its Passenger business to Joby Aviation, marking a strategic shift to focus entirely on organ logistics and medical services [1][3] Company Overview - The rebranding to Strata Critical Medical is complete, and the company will now trade under the ticker symbol SRTA [2] - Strata Critical Medical specializes in time-critical logistics solutions and medical services, particularly in organ transplant logistics, leveraging an asset-light aircraft network [7] Financial Performance - The company anticipates a decrease in adjusted unallocated corporate expenses and software development costs to approximately $3.5 million per quarter by Q4 2025 [4] - Revenue for the full year 2025 is projected to be between $160 million and $170 million, with expectations of double-digit adjusted EBITDA [9] Strategic Focus - The company aims to expand its portfolio of services through organic growth, strategic partnerships, and acquisitions, supported by a strong financial position [3][7] - Strata's logistics solution offers a unique vantage point into various growth opportunities in the medical services sector [3] Upcoming Events - An investor day is planned for this fall, with more details to be provided in the coming weeks [5]